Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?

被引：62

作者：

Muntean, Danina M. ^{[1
,2
]}

Thompson, Paul D. ^{[3
]}

Catapano, Alberico L. ^{[4
]}

Stasiolek, Mariusz ^{[5
]}

Fabis, Jaroslaw ^{[6
]}

Muntner, Paul ^{[7
]}

Serban, Maria-Corina ^{[1
,7
]}

Banach, Maciej ^{[8
,9
]}

机构：

[1] Victor Babes Univ Med & Pharm Timisoara, Dept Pathophysiol Funct Sci, Timisoara, Romania

[2] Victor Babes Univ Med & Pharm Timisoara, Ctr Translat Res & Syst Med, Timisoara, Romania

[3] Hartford Hosp, Div Cardiol, Hartford, CT 06115 USA

[4] Univ Milan, IRCCS Multimed, Dept Pharmacol & Biomol Sci, Milan, Italy

[5] Polish Mothers Mem Hosp, Res Inst Lodz, Dept Neurol, Lodz, Poland

[6] Med Univ Lodz, Dept Arthroscopy Minimally Invas Surg & Sports Tr, Lodz, Poland

[7] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA

[8] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Hypertens, Lodz, Poland

[9] Med Univ Lodz, HARC, Lodz, Poland

来源：

DRUG DISCOVERY TODAY | 2017年 / 22卷 / 01期

关键词：

COA REDUCTASE INHIBITORS; MITOCHONDRIAL OXIDATIVE STRESS; SQUALENE SYNTHASE INHIBITOR; SKELETAL-MUSCLE; CREATINE-KINASE; SIMVASTATIN; THERAPY; TOXICITY; COENZYME-Q10; INTOLERANCE;

D O I：

10.1016/j.drudis.2016.09.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Over the past three decades, statins have become the cornerstone of prevention and treatment of atherosclerotic cardiovascular and metabolic diseases. Albeit generally well tolerated, these drugs can elicit a variety of muscle-associated symptoms that represent the most important reason for treatment discontinuation. Statin-associated myopathy has been systematically underestimated by randomized controlled trials as compared with the incidence observed in clinical practice and obtained from patient registries. There are several reasons for this discrepancy, among which the lack of reliable diagnostic tests and a validated questionnaire to assess muscle symptoms are recognized as unmet needs. Here, we review the cellular and molecular mechanisms underlying statin-associated myopathy and discuss the experimental and clinical data on various biomarkers to diagnose and predict muscle-related complaints.

引用

页码：85 / 96

页数：12

共 131 条

[1] Statin-induced myopathy: a review and update [J].

Abd, Thura T. ;

Jacobson, Terry A. .

EXPERT OPINION ON DRUG SAFETY, 2011, 10 (03) :373-387

[2] Phenotype Standardization for Statin-Induced Myotoxicity [J].

Alfirevic, A. ;

Neely, D. ;

Armitage, J. ;

Chinoy, H. ;

Cooper, R. G. ;

Laaksonen, R. ;

Carr, D. F. ;

Bloch, K. M. ;

Fahy, J. ;

Hanson, A. ;

Yue, Q-Y ;

Wadelius, M. ;

Maitland-van der Zee, A. H. ;

Voora, D. ;

Psaty, B. M. ;

Palmer, C. N. A. ;

Pirmohamed, M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (04) :470-476

[3] The role of mitochondria in statin-induced myopathy [J].

Apostolopoulou, Maria ;

Corsini, Alberto ;

Roden, Michael .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2015, 45 (07) :745-754

[4] Identification of 1-and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling [J].

Aranibar, Nelly ;

Vassallo, Jeffrey D. ;

Rathmacher, John ;

Stryker, Steve ;

Zhang, Yingru ;

Dai, Jun ;

Janovitz, Evan B. ;

Robertson, Don ;

Reily, Michael ;

Lowe-Krentz, Linda ;

Lehman-McKeeman, Lois .

ANALYTICAL BIOCHEMISTRY, 2011, 410 (01) :84-91

[5] The safety of statins in clinical practice [J].

Armitage, Jane .

LANCET, 2007, 370 (9601) :1781-1790

[6] Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial [J].

Armitage, Jane ;

Bowman, Louise ;

Wallendszus, Karl ;

Bulbulia, Richard ;

Rahimi, Kazem ;

Haynes, Richard ;

Parish, Sarah ;

Peto, Richard ;

Collins, Rory ;

Meade, T. ;

Sleight, P. ;

Collins, R. ;

Armitage, J. ;

Bowman, L. ;

Parish, S. ;

Peto, R. ;

Barton, J. ;

Bray, C. ;

Wincott, E. ;

Dayanandan, R. ;

Clarke, R. ;

Graham, I. ;

Simpson, D. ;

Warlow, C. ;

Wilken, D. ;

Tobert, J. ;

Mushner, T. ;

Doll, R. ;

Wilhelmsen, L. ;

Fox, K. ;

Hill, C. ;

Sandercock, P. ;

Webster, J. ;

Henderson, J. ;

Nixon, A. ;

Lackie, S. ;

Thompson, J. ;

Brown, M. ;

Blackwood, S. ;

Morgan, M. ;

Rhoden, W. ;

Saeed, B. ;

Houghton, M. ;

Nicholson, A. ;

Simpson, C. ;

Hoburn, B. ;

Cooper, I. ;

Gallivan, A. ;

Pickerell, E. ;

Hancock, J. .

LANCET, 2010, 376 (9753) :1658-1669

[7] Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance [J].

Ballard, Kevin D. ;

Parker, Beth A. ;

Capizzi, Jeffrey A. ;

Grimaldi, Adam S. ;

Clarkson, Priscilla M. ;

Cole, Stephanie M. ;

Keadle, Justin ;

Chipkin, Stuart ;

Pescatello, Linda S. ;

Simpson, Kathleen ;

White, C. Michael ;

Thompson, Paul D. .

ATHEROSCLEROSIS, 2013, 230 (01) :121-124

[8]

Banach M, 2015, EUR HEART J, V36, P1047

[9] Lipids, blood pressure and kidney update 2015 [J].

Banach, Maciej ;

Aronow, Wilbert S. ;

Serban, Maria-Corina ;

Rysz, Jacek ;

Voroneanu, Luminita ;

Covic, Adrian .

LIPIDS IN HEALTH AND DISEASE, 2015, 14

[10] Statin therapy and plasma coenzyme Q10 concentrations-A systematic review and meta-analysis of placebo-controlled trials [J].

Banach, Maciej ;

Serban, Corina ;

Ursoniu, Sorin ;

Rysz, Jacek ;

Muntner, Paul ;

Toth, Peter P. ;

Jones, Steven R. ;

Rizzo, Manfredi ;

Glasser, Stephen P. ;

Watts, Gerald F. ;

Blumenthal, Roger S. ;

Lip, Gregory Y. H. ;

Mikhailidis, Dimitri P. ;

Sahebkar, Amirhossein .

PHARMACOLOGICAL RESEARCH, 2015, 99 :329-336

← 1 2 3 4 5 6 7 8 9 10 →